In line with this, PI3K inhibitors have been shown to counteract resistance to immune checkpoint blockade in a mouse tumor model [93] and clinical trials using PI3K inhibitors as a combination therapy together with immune checkpoint inhibitors are ongoing [94,95]. The gene discussed is PIK3CA; the disease is neoplasm.